BOSTON--(BUSINESS WIRE)--Corsera Health, Inc., leading the future of cardiovascular health through prediction and prevention, today announced the filing of a clinical trial notification (CTN) to ...

This milestone follows the completion of dosing in the single ascending dose (SAD) portion of the study. According to data reviewed to date, no serious or dose-limiting adverse events have been ...

Old metals don’t die, they wait for a technology to be invented so they can stage a comeback, which is exactly what’s happening with tin, which has a rising price thanks to excellent fundamentals of ...

Some protein powders and shakes contain unsafe levels of lead, according to a Consumer Reports investigation. In the report, published Tuesday, Consumer Reports analyzed 23 protein powders and shakes ...

Much has changed since Consumer Reports first tested protein powders and shakes. Over the past 15 years, Americans’ obsession with protein has transformed what had been a niche product into the ...

LONDON, Oct 3 (Reuters) - The tin market is once again bubbling on supply chain trouble, this time in Indonesia, where the government has launched a sweeping clamp-down on illegal mining. London Metal ...

Phase IIb data of Metsera Inc.’s lead GLP-1 receptor agonist, MET-097i, showed significant weight loss and good tolerability, supporting a phase III start later this year, and validating Pfizer Inc.’s ...

A series where we methodologically and obsessively try new products to tell you if they’re worth it so you don’t have to do all that work yourself. Read more reviews here. One of the hottest topics of ...

OSHKOSH—One of three companies seeking authorization for a 100-octane-rated unleaded avgas fuel should complete the first phase of an extended transition process in less than two years, a U.S. FAA ...

A cooperative research team from Beijing University of Chemical Technology and Linköping University introduce a redox energy barrier management strategy to enhance the performance of narrow-bandgap ...

Alzamend Neuro, Inc. (NASDAQ:ALZN) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy human subjects. This study follows the ...